Our recent RWE study detailed the comorbidity burden of Finnish multiple myeloma (MM) patients diagnosed between 2005 and 2016. Cardiovascular diseases (CVDs) and secondary malignancies were the most common groups of comorbid diseases and recorded as the main cause of death in c. 19% of cases during the follow-up. This publication (Toppila et al., 2022) represents a continuation work of our previously published study (Toppila et al., 2021), which outlined the patient characteristics and survival outcomes of this study population. The study was carried out by the experts at Takeda Oy, Medaffcon Oy, Helsinki University Hospital, and Helsinki University.
Multiple myeloma is a hematologic cancer predominantly affecting the elderly, with median age at diagnosis 70 years. Many MM patients are affected by significant comorbidities such as CVDs and secondary malignancies that impact both treatment decisions and ultimately patient mortality. The study utilized national healthcare registries to collate diagnoses and cause-of-death data, which were interrogated using various multistate time-to-event models. Comorbidities were defined according to recorded specialty care diagnoses and grouped according to the Charlson comorbidity index (CCI) definitions with minor modifications, to provide a robust comparison to past and future studies.
In the year preceding MM diagnosis, nearly all patients had records of specialty care visits. CCI-defined comorbidities were recorded for 38% of the cohort within this timeframe, with 27.9% presenting with CVDs, 4.8% having suffered a major adverse cardiac event (MACE) and 16.8% presenting with secondary malignancies at diagnosis. Cumulative incidence of recorded comorbidities further increased after MM diagnosis, with CVD and MACE incidence more than doubling to 57.1% and 11.4% in 2 years, respectively, whilst secondary malignancy nearly doubled to 33% in 5 years post MM diagnosis in the surviving study population. MM remained the main cause of death throughout the study (between 70.2-74.4%), with CVDs and secondary malignancies accounting for 9-12% of main causes of death each.
Our analyses showed that older MM male patients were had an increased risk for MACE, secondary malignancies and death. The study also confirmed that the overall comorbidity burden in MM patients is high, with many comorbidities recorded after MM diagnoses. This increased incidence may reflect an improved focus on sufficient comorbidity management post MM diagnosis to support optimal MM treatment.
Comorbidity characteristics of multiple myeloma patients diagnosed in Finland 2005-2016. Toppila I, Kysenius K, Miettinen T, Lassenius MI, Lievonen J, Anttila P. Annals of Hematology (2022)
Read a summary of Medaffcon’s earlier study on multiple myeloma – Characteristics and survival trends in Finnish multiple myeloma patients—a nationwide real-world evidence study
My list of publications includes over 20 peer-reviewed scientific articles. One of them is a special one because the Finnish Current Care Guidelines mention it for heart failure. This blog discusses the impact of research by Medaffcon on treatment practices.
A study published in January 2024 in the Scandinavian Journal of Gastroenterology has revealed that the treatment of adults with Short Bowel Syndrome (SBS-IF) clearly has significant room for improvement. Patients require extensive amounts of healthcare services, and their mortality rate is elevated.
Our latest multiple myeloma publication describes how complex multiple myeloma treatment patterns were assembled from data available in the Helsinki University Hospital data lake, Finland, how the treatments have changed in 2013–2019, and what the estimated treatment costs are in multiple myeloma.The study published online in October 2023 was carried out by the experts at Medaffcon Oy, Sanofi Oy, and Helsinki University Hospital, Finland.